ALNY (Alnylam Pharmaceuticals, Inc.) Stock Financials & Earnings

ALNYAlnylam Pharmaceuticals, Inc.

Mkt Cap$43B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$3.7B

Net Income (TTM)$314M

EPS (TTM)$2.26

Free Cash Flow (TTM)$465M

Gross Margin81.7%

Op. Margin13.5%

Net Margin8.4%

FCF Margin12.5%

P/S Ratio (TTM)11.6x

P/E Ratio (TTM)137.6x

YoY Rev Growth+65.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$319M	$264M	-$150M
Q2 23	$319M	$233M	-$230M
Q3 23	$751M	$666M	$214M
Q4 23	$440M	$354M	-$116M
Q1 24	$494M	$428M	-$43M
Q2 24	$660M	$591M	$49M
Q3 24	$501M	$415M	-$77M
Q4 24	$593M	$490M	-$105M
Q1 25	$594M	$523M	$18M
Q2 25	$774M	$631M	-$16M
Q3 25	$1.2B	$1.1B	$368M
Q4 25	$1.1B	$829M	$132M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$231M	$184M	—
Q2 23	$249M	$215M	—
Q3 23	$253M	$199M	—
Q4 23	$272M	$198M	—
Q1 24	$261M	$211M	—
Q2 24	$294M	$248M	—
Q3 24	$271M	$221M	—
Q4 24	$300M	$295M	—
Q1 25	$265M	$240M	—
Q2 25	$324M	$323M	—
Q3 25	$359M	$322M	—
Q4 25	$372M	—	$325M

Revenue Segments

Quarter	Product	Royalty	Givlaari	Onpattro
Q2 23	$306M	$7M	—	—
Q1 24	$365M	—	$58M	$69M
Q1 25	$469M	—	$67M	$49M
Q2 25	$672M	—	$81M	$53M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$672M	$1.4B	$2.1B
Q2 23	$658M	$1.4B	$2.1B
Q3 23	$1.0B	$1.4B	$2.4B
Q4 23	$813M	$1.6B	$2.4B
Q1 24	$682M	$1.7B	$2.4B
Q2 24	$968M	$1.7B	$2.6B
Q3 24	$1.1B	$1.7B	$2.8B
Q4 24	$966M	$1.7B	$2.7B
Q1 25	$1.0B	$1.6B	$2.6B
Q2 25	$1.1B	$1.7B	$2.9B
Q3 25	$1.5B	$1.2B	$2.7B
Q4 25	$1.7B	$1.3B	$2.9B

Shares Outstanding

Revenue Per Employee

Revenue / Employee